Cagrilintide (acetate)

Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies[1][2][3].

O=C(CC[C@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H]1[C@@H](C)O)=O)C)=O)[C@@H](C)O)=O)CC(N)=O)=O)CSSC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N2[C@H](C(N[C@H](C(N[C@H](C(N3[C@H](C(N4[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N5[C@H](C(N)=O)CCC5)=O)[C@@H](C)O)=O)CC(N)=O)=O)CO)=O)=O)C(C)C)=O)CC(N)=O)=O)[C@@H](C)O)=O)CCC4)=O)CCC3)=O)CC(C)C)=O)[C@H](CC)C)=O)CCC2)=O)=O)CC6=CC=CC=C6)=O)CC(N)=O)=O)CC(N)=O)=O)CO)=O)CO)=O)CC7=CNC=N7)=O)CCCNC(N)=N)=O)CC(C)C)=O)CC8=CC=CC=C8)=O)CCC(O)=O)=O)C)=O)CC(C)C)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)[C@@H](C)O)=O)C)=O)NC1=O)=O)CCCCN.O=C(C)O.[x]

[1]Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021 Aug 12;64(15):11183-11194. |[2]Fletcher MM, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. J Pharmacol Exp Ther. 2021 Jun;377(3):417-440. |[3]Dehestani B, et al. Amylin as a Future Obesity Treatment. J Obes Metab Syndr. 2021 Dec 30;30(4):320-325.